Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder

被引:5
|
作者
Park, Seo Yeon
Kim, Eun Joo
Cheon, Keun-Ah
机构
[1] Yonsei Univ, Dept Psychiat, Coll Med, Seoul 120752, South Korea
[2] Yonsei Univ, Inst Behav Sci Med, Coll Med, Seoul 120752, South Korea
关键词
SEROTONIN TRANSPORTER GENE; DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; DOSE-RESPONSE; ALLELIC VARIATION; TOURETTE SYNDROME; RECEPTOR GENE; ADHD; DOPAMINE; METAANALYSIS;
D O I
10.1089/cap.2014.0168
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives: The purpose of this study is to examine the relationship between 5-HTTLPR polymorphism (44-bp insertion/deletion polymorphism of serotonin transporter gene) and methylphenidate (MPH) treatment response, as well as the association between the adverse events of MPH treatment and 5-HTTLPR polymorphism in children with attention-deficit/hyperactivity disorder (ADHD). Methods: A total of 114 children with ADHD (mean age 9.081.94 years) were recruited from the child psychiatric clinic in a hospital in South Korea. We have extracted the genomic DNA of the subjects from their blood lymphocytes and analyzed 5-HTTLPR polymorphism of the SLC6A4 gene. All children were treated with MPH for 8 weeks, with clinicians monitoring both the improvement of ADHD symptoms and the side effects. We compared the response to MPH treatment and adverse events among those with the genotype of 5-HRRLPR polymorphism. Results: There was no significant association between the 5-HTTLPR genotype and the response to MPH treatment in children with ADHD. Subjects with the S/L+L/L genotype tended to have tics and nail biting (respectively, p<0.001, p=0.017). Conclusions: The results of this study do not support the association between the 5-HTTLPR polymorphism and treatment response with MPH in ADHD. However, our findings suggest the association between 5-HTTLPR polymorphism and the occurrence of tics and nail-biting as an adverse event of methylphenidate. This may aid in our understanding of the genetic contribution and genetic susceptibility of a particular allele in those ADHD patients with tics or nail biting.
引用
收藏
页码:633 / 640
页数:8
相关论文
共 50 条
  • [31] Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate
    E M Bruxel
    A Salatino-Oliveira
    J P Genro
    C P Zeni
    G V Polanczyk
    R Chazan
    L A Rohde
    M H Hutz
    The Pharmacogenomics Journal, 2013, 13 : 476 - 480
  • [32] Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment
    Kara, Tayfun
    Akaltun, Ismail
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (04) : 484 - 484
  • [33] OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder
    Antoni Ramos-Quiroga, J.
    Corominas, Margarida
    Castells, Xavier
    Bosch, Rosa
    Casas, Miguel
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (08) : 1121 - 1131
  • [34] Methylphenidate transdermal system for the treatment of attention-deficit/hyperactivity disorder
    Rugino, Thomas
    FUTURE NEUROLOGY, 2007, 2 (06) : 613 - 620
  • [35] An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/hyperactivity disorder
    Froelich, Jan
    Banaschewski, Tobias
    Doepfner, Manfred
    Goertz-Dorten, Anja
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (08) : 1169 - 1183
  • [36] Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate
    Wolraich, ML
    Doffing, MA
    CNS DRUGS, 2004, 18 (04) : 243 - 250
  • [37] BUPROPION VERSUS METHYLPHENIDATE IN THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
    BARRICKMAN, LL
    PERRY, PJ
    ALLEN, AJ
    KUPERMAN, S
    ARNDT, SV
    HERRMANN, KJ
    SCHUMACHER, E
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (05): : 649 - 657
  • [38] Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate
    Mark L. Wolraich
    Melissa A. Doffing
    CNS Drugs, 2004, 18 : 243 - 250
  • [39] Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder
    Olfson, Mark
    Marcus, Steven C.
    Zhang, Huabin F.
    Wan, George J.
    JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (07): : 570 - 577
  • [40] Hiccups in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment
    Akaltunl, Ismail
    Ayaydin, Hamza
    Kara, Tayfun
    PSYCHIATRY AND BEHAVIORAL SCIENCES, 2018, 8 (02): : 86 - 88